A Study of CS-3150 to Evaluate Efficacy and Safety in Patients with Primary Aldosteronism

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223294

Enrollment

Registered

2016-08-17

Start date

2016-10-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary aldosteronism

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Esaxerenone Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational mat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Male and female subjects aged 20 years or older at informed consent 2) Patients diagnosed primary aldosteronism by screening test of PAC and ARR, and confirmatory testing 3) Patients satisfying following blood pressure; i)-sitting SBP >= 140 mmHg and = 90 mmHg and <110 mmHg, ii) between two measurement difference =<30/15 mmHg)

Exclusion criteria

Exclusion criteria: 1)Secondary hypertension except primary aldosteronism or hypertensive emergency 2)Patients diagnosed diabetic nephropathy 3)Patients with type 1 diabetes 4)eGFR = 5.1 mEq/L

Design outcomes

Primary

Measure	Time frame
safety efficacy - Change from baseline in sitting systolic and diastolic blood pressure at the end of treatment - Adverse events	—

Secondary

Measure	Time frame
efficacy -Time course of sitting systolic and diastolic blood pressure -Proportion of patients achieving sitting blood pressure goal	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026